挪威类风湿关节炎与银屑病关节炎的发病率、社会人口学因素及治疗渗透率
该研究基于挪威全国注册数据,评估2011-2015年成人RA和PsA的发病率、社会人口学关联及治疗渗透率。RA和PsA发病率分别为42/10万人年和26/10万人年,高等教育水平者发病率较低。RA患者1年内合成DMARD使用率高于PsA(82.4% vs 57.4%),但生物制剂使用率相当(9.4% vs 9.5%)。
要点
- 挪威RA和PsA发病率分别为42/10万人年和26/10万人年,与北欧其他国家相似。
- RA发病高峰在70-79岁,PsA发病高峰在50-59岁。
- 高等教育水平与RA和PsA较低发病率相关,PsA早期合成DMARD使用率低于RA。
核心结论
- 挪威基于注册的RA和PsA发病率与北欧其他国家相似,但略高于既往挪威研究。
- 较高社会经济地位与RA和PsA较低发病率相关。
- PsA早期合成DMARD使用率低于RA,但生物制剂处方频率相当。
研究设计与样本
- 研究结合挪威全国注册数据,覆盖全部挪威成年人口(年龄≥18岁)。
- 从挪威患者注册库识别2011-2015年新发RA和PsA病例,定义为首次和第二次医疗接触记录RA/PsA诊断编码,且首次发作后两年内至少一次内科或风湿科就诊记录RA/PsA编码。
- 从挪威处方数据库获取配发的DMARD处方,排除索引日期前12个月以上已配发DMARD或医院给予生物制剂者。
主要发现
- 挪威RA/PsA发病率为42/26每10万人年(女性55/28,男性28/23)。
- RA发病高峰在男女均为70-79岁,PsA发病高峰在50-59岁。
- 年龄和性别标准化后,高等教育水平者RA和PsA发病率较低。
- 索引日期后一年内,82.4%/57.4%的RA/PsA患者使用合成DMARD,9.4%/9.5%使用生物制剂。
临床怎么用
- 挪威RA和PsA发病率数据与北欧其他国家相似,可作为流行病学参考。
- PsA早期合成DMARD使用率低于RA,但生物制剂使用率相当,提示治疗策略差异。
- 高等教育水平与较低发病率相关,提示社会经济因素可能影响疾病发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate nationwide incidence, sociodemographic associations and treatment penetration of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in Norway. METHODS: The study combined data from nationwide registries on the total Norwegian adult population (age ≥ 18). From the Norwegian Patient Registry, incident RA and PsA cases during 2011-2015 were identified with records of first and second healthcare episodes listing RA/PsA diagnostic codes, and ≥ 1 episode in an internal medicine or rheumatology unit with RA/PsA code during the two-year period after the first episode. Dispensed DMARD prescriptions were obtained from the Norwegian Prescription Database. Persons with dispensed DMARD prescriptions or biologic DMARDs given in hospitals > 12 months before the index date were excluded. RESULTS: Incidence of RA/PsA in Norway was 42/26 per 100,000 person-years (55/28 among women and 28/23 among men). RA peak incidence was observed at ages 70-79 in both sexes, whereas the peak incidence of PsA occurred at ages 50-59. Age- and sex-standardized incidences of RA and PsA were lower among persons with higher education levels. Within a year from the index date, 82.4/57.4% of RA/PsA patients used synthetic DMARDs while 9.4/9.5% used biologic DMARDs. CONCLUSIONS: Register-based incidence estimates for RA and PsA in Norway are similar to other Nordic countries, but slightly higher than in previous Norwegian studies. Furthermore, we found that higher socioeconomic status was associated with lower incidence of both RA and PsA. Although conventional synthetic DMARDs were less often used in early PsA than RA, frequency of biologic DMARD prescriptions was comparable.
引用
- Kerola AM, Sexton J, Wibetoe G, et al. Incidence, sociodemographic factors and treatment penetration of rheumatoid arthritis and psoriatic arthritis in Norway. Semin Arthritis Rheum. 2021. PMID: 34450506. doi:10.1016/j.semarthrit.2021.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。